MEK-ERK inhibition potentiates WAY-600-induced anti-cancer efficiency in preclinical hepatocellular carcinoma (HCC) models

MLA

Dexin Kong, et al. “MEK-ERK Inhibition Potentiates WAY-600-Induced Anti-Cancer Efficiency in Preclinical Hepatocellular Carcinoma (HCC) Models.” Biochemical and Biophysical Research Communications, vol. 474, May 2016, pp. 330–37. EBSCOhost, https://doi.org/10.1016/j.bbrc.2016.04.099.

APA

Dexin Kong, Gongying Chen, Zhengrong Wang, Yaohua Fan, Peng Zhang, & Kaifeng Wang. (2016). MEK-ERK inhibition potentiates WAY-600-induced anti-cancer efficiency in preclinical hepatocellular carcinoma (HCC) models. Biochemical and Biophysical Research Communications, 474, 330–337. https://doi.org/10.1016/j.bbrc.2016.04.099

Chicago

Dexin Kong, Gongying Chen, Zhengrong Wang, Yaohua Fan, Peng Zhang, and Kaifeng Wang. 2016. “MEK-ERK Inhibition Potentiates WAY-600-Induced Anti-Cancer Efficiency in Preclinical Hepatocellular Carcinoma (HCC) Models.” Biochemical and Biophysical Research Communications 474 (May): 330–37. doi:10.1016/j.bbrc.2016.04.099.